Headquartered in Seattle and Singapore, Callio Therapeutics is focused on realizing the promise of multi-payload antibody-drug conjugates to transform cancer patient outcomes. The company is developing next-generation, multi-payload antibody-drug conjugates (ADCs) that feature differentiated payload and linker technologies that enable targeted delivery of multi agents to tumor cells to maximize therapeutic benefit. Callio Therapeutics’ lead program is a HER2-targeted dual-payload ADC. Callio Therapeutics was created by Frazier Life Sciences, a longstanding investment firm focused on innovative therapeutics, based on ADC technology and programs exclusively in-licensed from Hummingbird Bioscience.
Investors 2
| Date | Name | Website |
| 31.03.2025 | Jeito Capi... | jeito.life |
| 01.07.2025 | Omega Fund... | omegafunds... |
Mentions in press and media 3
| Date | Title | Description |
| 03.03.2025 | Callio Therapeutics Closes US$187M in Series A Funding | Callio Therapeutics, a Seattle, WA- and Singapore-based biotechnology company focused on developing multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy, raised US$187M in Series A funding. The round was led by Frazier Li... |
| 03.03.2025 | Callio Therapeutics Launches with US$187 Million Series A to Advance Multi-Payload Antibody-Drug Conjugate Platform Through Clinical Proof-of-Concept | Frazier Life Sciences launches Callio Therapeutics based on multi-payload antibody-drug conjugate technology and programs exclusively in-licensed from Singapore-based Hummingbird Bioscience Financing led by Frazier Life Sciences with signif... |
| - | Callio Therapeutics | “We’re advancing next-gen multi-payload ADCs with unique payload and linker tech to deliver dual agents to tumor cells, maximizing benefits for cancer patients.” |